<SEC-DOCUMENT>0001193125-25-210031.txt : 20250922
<SEC-HEADER>0001193125-25-210031.hdr.sgml : 20250922
<ACCEPTANCE-DATETIME>20250922074204
ACCESSION NUMBER:		0001193125-25-210031
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250922
DATE AS OF CHANGE:		20250922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		251328435

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d927871ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule</B><B></B><B><FONT
STYLE="white-space:nowrap">&nbsp;14a-6(e)(2))</FONT> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>STAAR SURGICAL COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>On September&nbsp;22, 2025, STAAR Surgical Company (&#8220;STAAR&#8221;) issued the following press
release:</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g927871g0922082505710.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STAAR Surgical Announces Expiration of &#8220;Window Shop&#8221; Period; No Competing Acquisition
Proposals Received </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Reinforces STAAR Board&#8217;s Determination that Alcon Merger Maximizes Stockholder Value and is Best Path
Forward for STAAR Stockholders </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LAKE FOREST, CA, September</B><B></B><B>&nbsp;22, 2025 </B>&#8212;- STAAR Surgical Company (NASDAQ: STAA), the
global leader in phakic IOLs with the EVO family of Implantable Collamer<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Lenses (EVO ICL<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) for vision correction, today announced the
expiration of the <FONT STYLE="white-space:nowrap">45-day</FONT> &#8220;window shop&#8221; period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The &#8220;window shop&#8221; period expired at
11:59 p.m., Eastern Time, on September&nbsp;19, 2025, and no competing acquisition proposal was received despite Broadwood Partners&#8217; active exploration of alternative buyers over the past 45 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;The expiration of the &#8216;window shop&#8217; period with no competing acquisition proposal reinforces the Board&#8217;s conclusion that the Alcon
merger maximizes value for STAAR stockholders,&#8221; said Stephen Farrell, CEO of STAAR. &#8220;In an effort to derail the Alcon merger, Broadwood Partners has repeatedly claimed that other parties are interested and capable of making a proposal.
However, the Company has not received any competing proposal since media reports of takeover interest in STAAR first surfaced in July 2024, nor since the Alcon merger agreement was announced.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Broadwood has provided significant input on the composition of the STAAR Board and management team, including recommending three of the Board&#8217;s
current six members and voting for all of STAAR&#8217;s directors at STAAR&#8217;s 2025 Annual Meeting. The Board extensively considered Broadwood&#8217;s opposition to the Alcon merger agreement as well as its fiduciary responsibility to all
stockholders, including Broadwood, before unanimously approving the Alcon agreement. Collectively, the Board and management team understand the market risks, trends, and opportunities better than Broadwood, and Broadwood&#8217;s opposition to the
transaction is unfounded,&#8221; continued Mr.&nbsp;Farrell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STAAR stockholders are encouraged to consider the following additional facts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to entering into the Alcon merger agreement, STAAR&#8217;s Board conducted an extensive evaluation of the
Company&#8217;s strategic alternatives, including continuing as a standalone company. The expiration of the &#8220;window shop&#8221; period and absence of a competing proposal further validate the Board&#8217;s determination that the Alcon merger
agreement maximizes stockholder value and is the best path forward for the Company and STAAR stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">More than a year before STAAR entered into the Alcon merger agreement, there were market rumors and public
reports regarding potential M&amp;A interest in STAAR, yet in the ensuing months, no competing proposal was received; and </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Broadwood has repeatedly indicated that it has been in contact with possible strategic and financial parties
interested in acquiring the Company as an alternative to the Alcon merger. However, despite the &#8220;window shop&#8221; period providing a clear path to make a competing proposal with a nominal termination fee, no competing proposal has been
received. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#8220;window shop&#8221; provision in the Alcon merger agreement reflects the STAAR Board&#8217;s commitment to
maximizing stockholder value and was aggressively negotiated by STAAR. This provision enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger agreement with a nominal termination fee of 1% of the Alcon merger
transaction value, as further described in the Alcon merger agreement. This nominal fee compares to the 3% termination fee that would be payable to Alcon if STAAR terminates the Alcon merger agreement to accept a superior proposal received after
September&nbsp;19, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $28.00 per share <FONT STYLE="white-space:nowrap">all-cash</FONT> consideration in the Alcon merger agreement provides STAAR
stockholders with compelling, certain, and immediate cash value at a significant premium across multiple measures, including a 51% premium to the closing price of STAAR common stock on August&nbsp;4, 2025 (the day prior to the agreement being
announced) and a 59% premium to STAAR&#8217;s <FONT STYLE="white-space:nowrap">90-day</FONT> volume weighted average price as of that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broadwood is
asking STAAR stockholders to forfeit the <FONT STYLE="white-space:nowrap">all-cash,</FONT> premium value provided by the Alcon merger agreement and instead underwrite the significant risks inherent in STAAR as a standalone company. If the
transaction is not approved, STAAR expects stockholders will be exposed to significant value destruction as compared to the $28 per share merger value. The Company&#8217;s stock was trading at $18.49 prior to the announcement of the agreement, and
preliminary third quarter trends signal that the business challenges which have been adversely impacting STAAR&#8217;s financial results are continuing. STAAR&#8217;s stockholders are encouraged to reject Broadwood&#8217;s flawed and misleading
claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The STAAR Board of Directors strongly recommends STAAR stockholders vote &#8220;FOR&#8221; the merger proposal on the WHITE proxy card TODAY.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders with questions about voting their shares should contact STAAR&#8217;s proxy solicitor, Innisfree M&amp;A Incorporated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For stockholders: (877) <FONT STYLE="white-space:nowrap">750-8233</FONT> (toll-free) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For banks and brokerage firms: (212) <FONT STYLE="white-space:nowrap">750-5833</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About STAAR Surgical </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STAAR Surgical (NASDAQ: STAA) is
the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR
has been designing, developing, manufacturing, and marketing advanced Implantable Collamer<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL&#8217;s are
clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye&#8217;s natural crystalline lens. Its EVO ICL<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> product line provides visual freedom
through a quick, minimally invasive procedure. STAAR has sold more than 3&nbsp;million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in
California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information About the Merger and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication relates to the proposed transaction involving STAAR. In connection with the proposed transaction, STAAR has filed relevant materials with
the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including STAAR&#8217;s definitive proxy statement on Schedule 14A (the &#8220;Proxy Statement&#8221;), on September&nbsp;16, 2025. The Proxy Statement was first sent to STAAR
stockholders on September&nbsp;16, 2025. This communication is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY
VOTING DECISION, STOCKHOLDERS OF STAAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC&#8217;s website, www.sec.gov, or by
visiting STAAR&#8217;s investor relations website, https://investors.staar.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation
of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there
be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under SEC rules, STAAR and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the
solicitation of proxies from the holders of STAAR&#8217;s common stock in connection with the proposed transaction. Information about the directors and executive officers of STAAR and their ownership of STAAR&#8217;s common stock is set forth in the
Proxy Statement, the definitive proxy statement for STAAR&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Annual Proxy Statement&#8221;), which was filed with the SEC on April&nbsp;24, 2025 (and which is available at
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025058174/staa-20250424.htm), including the sections captioned &#8220;Compensation of Directors,&#8221; &#8220;Information Regarding Executive Officers&#8221; and &#8220;Security
Ownership of Principal Shareholders and Management,&#8221; or its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27, 2024, which was filed with the SEC on February&nbsp;21, 2025 (and which is
available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025024813/staa-20241227.htm), and in other documents filed by STAAR with the SEC. To the extent holdings of such participants in STAAR&#8217;s securities have changed
since the amounts described in the Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC by STAAR&#8217;s directors
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and executive officers. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a
description of their direct and indirect interests, by security holdings or otherwise, will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information covered by
this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; and similar terms. All statements in this communication that are not
statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results,
performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1)&nbsp;the occurrence of any event, change or other circumstances that could give rise to
the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2)&nbsp;the failure to obtain approval of the proposed transaction from STAAR&#8217;s stockholders;
(3)&nbsp;the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4)&nbsp;risks related to
disruption of management&#8217;s attention from STAAR&#8217;s ongoing business operations due to the proposed transaction; (5)&nbsp;the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel
and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6)&nbsp;the ability of STAAR to meet expectations regarding the timing and completion of the
transaction; (7)&nbsp;the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8)&nbsp;the possibility that STAAR&#8217;s stock price may decline significantly if the proposed transaction is not
consummated; and (9)&nbsp;other important factors set forth in the Proxy Statement under the caption &#8220;Risk Factors&#8221; and STAAR&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27,
2024 under the caption &#8220;Risk Factors,&#8221; as any such factors may be updated from time to time in STAAR&#8217;s other filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, STAAR undertakes no obligation to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STAAR Contacts:&#8195; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Niko Liu, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States: +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-303-7902</FONT></FONT> (ext 3023) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong:
<FONT STYLE="white-space:nowrap">+852-6092-5076</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nliu@staar.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investorrelations@staar.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Connie Johnson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 626 303 7902 (ext 2207) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cjohnson@staar.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucas Pers / Zach Genirs </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joele Frank, Wilkinson Brimmer Katcher
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-895-8692</FONT></FONT> / +1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">212-895-8653</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g927871g0922082505710.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g927871g0922082505710.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2L# 2(  A$! Q$!_\0
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MW6E7%Y=:;!-?VHM;IE_>0AMP4_6LSPGKL^OZ?>7,\:1F&^FME"=U1L _6H?
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M 9FD^']*T.*6+3K**!)7WN%'WCZT3^'M*N-8@U:2RC-] ,1S8PRCG_$UIT4
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M[%'F QYJDJV/3(K:HH H:7HVGZ+;?9].M8[>,G)"#ECZD]Z?!I5E;ZE<ZC%
MJW=R%667NP7H*N44 4M0TJRU5(4O8%E$$JS1YZJZ]"*35='L=;LOLFHVZSP;
MP^QO[PZ&KU% &!8^#-!TV]BO+6Q$<\1RC;V..,>M;]%% !1110 44F:,T +1
M29HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
/ M%)FC- "T4F:,T ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
